Oracle Corporation (ORCL) announced its new Life Sciences AI Data Platform today, designed to accelerate pharma R&D, but shares dropped 4.08% to $165.75 as the market focused on ongoing cost risks and broader tech sector worries.
- Morgan Stanley recently lowered its price target significantly from $320 to $213, citing the GPU-as-a-Service buildout as an EPS pressure point due to higher funding needs.
- The company faces ongoing securities lawsuits probing 2025 AI buildout bonds for alleged misrepresentations regarding debt requirements.